MAXION THERAPEUTICS
Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
• Investor syndicate comprised of LifeArc Ventures, Monograph Capital and BGF
• Funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class
Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments
• Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biology
• Reveals future prospects for developing precision medicines to modulate macrophages for the treatment of cancer by targeting tumour associated macrophage (TAMs) in the tumour microenvironment (TME)
We are delighted to announce that we have entered into a Strategic Partnership for the Development and cGMP Manufacturing Services for Vaccitech’s Adenoviral Vector programme. Pharmaron will become a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
- Eighth new technology partnership with major pharmaceutical and biotech companies since IPO
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS
- Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics
The new MagSi-DNA FFPE kit from AMSBIO enables quick and easy isolation of genomic DNA (gDNA) from mammalian formalin-fixed paraffin-embedded (FFPE) tissue or cell samples.
Developed using proprietary magnetic bead technology – the MagSi-DNA FFPE kit can be used for manual and automated isolation of gDNA from mammalian FFPE tissue or cell samples.
India stands as a promising power in the pharmaceutical industry
Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases
February 11th marks International Day of Women and Girls in science, the purpose of which is to promote the ‘full and equal access and participation of females in STEM’.
According to United Nations, “Gender equality, besides being a fundamental human right, is essential to achieve peaceful societies, with full human potential and sustainable development.”
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders